Vanda Pharmaceuticals (NASDAQ:VNDA) Reaches New 12-Month High – What’s Next?

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) shares hit a new 52-week high during trading on Wednesday . The company traded as high as $9.00 and last traded at $9.3980, with a volume of 3669100 shares trading hands. The stock had previously closed at $7.03.

More Vanda Pharmaceuticals News

Here are the key news stories impacting Vanda Pharmaceuticals this week:

• Positive Sentiment: FDA approved NEREUS (tradipitant) for prevention of vomiting induced by motion — the first new approved motion‑sickness drug in decades, creating a new commercial franchise and potential use against GLP‑1–related nausea; this approval is the primary catalyst driving bullish sentiment. Vanda Pharmaceuticals Announces FDA Approval of NEREUS
• Positive Sentiment: B. Riley raised its price target to $14 from $11, signaling increased analyst confidence in NEREUS’s commercial potential and supporting upside expectations. Vanda Pharmaceuticals price target raised to $14 from $11 at B. Riley
• Positive Sentiment: Sell‑side and commentary pieces highlight a 2026 “catalyst run” (NEREUS launch, Bysanti PDUFA) and note a strong cash balance (~$294M) and guidance that support funding multiple late‑stage launches — this reduces near‑term liquidity risk and frames upside from upcoming launches. Vanda’s 2026 Catalyst Run With Nereus Launch And Bysanti PDUFA In Focus
• Positive Sentiment: Unusual bullish options flow and extremely heavy equity volume suggest speculative and institutional buying interest around the approval and launch story (call volume spiked well above average). Article not provided
• Neutral Sentiment: Street coverage and headlines (Barron’s, Benzinga, Zacks, MSN) are amplifying the approval news, increasing visibility and short‑term trading interest; media attention can boost liquidity but may also amplify volatility. Vanda Pharmaceuticals Shares Jump 30% on Motion Sickness Drug Approval
• Negative Sentiment: Vanda reported recent quarterly losses (missed EPS and a net loss driven by higher R&D and SG&A), so the company remains in a strategic investment phase — commercial launch costs and execution risk could pressure margins and cash if revenues ramp slower than expected. Vanda’s 2026 Catalyst Run With Nereus Launch And Bysanti PDUFA In Focus

Analysts Set New Price Targets

Several brokerages recently issued reports on VNDA. Cantor Fitzgerald restated an “overweight” rating on shares of Vanda Pharmaceuticals in a research note on Wednesday, December 17th. Weiss Ratings restated a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a research report on Wednesday, October 8th. Wall Street Zen cut Vanda Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, November 28th. B. Riley boosted their price target on shares of Vanda Pharmaceuticals from $11.00 to $14.00 and gave the company a “buy” rating in a report on Wednesday. Finally, HC Wainwright restated a “buy” rating on shares of Vanda Pharmaceuticals in a research note on Monday, December 1st. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Vanda Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $13.13.

Vanda Pharmaceuticals Stock Up 25.5%

The firm has a market cap of $521.26 million, a price-to-earnings ratio of -6.21 and a beta of 0.60. The business’s 50-day moving average is $5.66 and its 200-day moving average is $5.07. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.10 and a current ratio of 3.12.

Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its quarterly earnings data on Wednesday, October 29th. The biopharmaceutical company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.07). Vanda Pharmaceuticals had a negative return on equity of 16.82% and a negative net margin of 39.70%.The firm had revenue of $56.26 million for the quarter, compared to the consensus estimate of $58.73 million. On average, equities analysts predict that Vanda Pharmaceuticals Inc. will post -1.12 EPS for the current year.

Hedge Funds Weigh In On Vanda Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of VNDA. Russell Investments Group Ltd. raised its holdings in shares of Vanda Pharmaceuticals by 456.6% in the third quarter. Russell Investments Group Ltd. now owns 6,495 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 5,328 shares during the last quarter. CWM LLC increased its position in Vanda Pharmaceuticals by 424.6% in the 2nd quarter. CWM LLC now owns 9,359 shares of the biopharmaceutical company’s stock valued at $44,000 after acquiring an additional 7,575 shares in the last quarter. PVG Asset Management Corp acquired a new stake in Vanda Pharmaceuticals in the 1st quarter valued at about $48,000. Quarry LP bought a new position in shares of Vanda Pharmaceuticals in the third quarter worth about $53,000. Finally, Cerity Partners LLC acquired a new position in shares of Vanda Pharmaceuticals during the second quarter worth approximately $69,000. Institutional investors and hedge funds own 88.14% of the company’s stock.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders and rare diseases. The company’s research and development efforts center on sleep-wake regulation, mood disorders, and movement disorders. Vanda’s mission is to address unmet medical needs by advancing novel molecules through clinical trials and regulatory review.

Vanda’s flagship commercial product is Hetlioz (tasimelteon), a melatonin receptor agonist approved by the U.S.